Treatment of Elderly Ovarian Cancer Patients in the Context of Controlled Clinical Trials: A Joint Analysis of the AGO Germany Experience
- 1 January 2012
- journal article
- research article
- Published by S. Karger AG in Onkologie
- Vol. 35 (3), 76-81
- https://doi.org/10.1159/000336829
Abstract
Background: Age remains a negative prognostic factor in ovarian cancer (OC). 3 separate analyses by the AGO (Arbeitsgemeinschaft Gynaekologische Onkologie) give insight into the treatment of elderly patients (EPs) in the context of controlled clinical trials (CCTs). Methods: 1 retrospective study evaluated the reasons for non-enrolment into CCTs of patients with advanced OC in AGO centers. 2 other exploratory age-specific analyses of a phase III trial in advanced OC treated with platinum/ paclitaxel evaluated (1) feasibility, toxicity and quality of life (QoL) and (2) the clinical outcome. Results: Non-study patients were significantly older (66.7 vs. 57.2 years). Reasons for non-enrolment were predominantly predefined exclusion criteria, numeric age, and the patient’s decision. The phase III trial confirmed an under-representation of EPs. Cycle delivery was significantly lower and discontinuation more frequent in EPs than in younger patients (YPs), although QoL, toxicity, cycle delays, and dose reductions were comparable. Delivery of cycles was prognostically significant in EPs but not YPs. The survival advantage of YPs remained significant even in completely debulked patients. Conclusion: There is some kind of investigator reservation for the treatment of EPs, which not only applies for the enrolment into clinical trials but also for the treatment, even under CCT conditions, with impact on outcome.Keywords
This publication has 16 references indexed in Scilit:
- Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trialsCancer, 2009
- Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: A systematic reviewGynecologic Oncology, 2009
- Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survivalBritish Journal of Cancer, 2008
- Feasibility, toxicity and quality of life of first-line chemotherapy with platinum/paclitaxel in elderly patients aged ≥70 years with advanced ovarian cancer—a study by the AGO OVAR GermanyAnnals of Oncology, 2007
- Carcinoma of the OvaryInternational Journal of Gynecology & Obstetrics, 2006
- Randomized Phase III Trial of Topotecan Following Carboplatin and Paclitaxel in First-line Treatment of Advanced Ovarian Cancer: A Gynecologic Cancer Intergroup Trial of the AGO-OVAR and GINECOJNCI Journal of the National Cancer Institute, 2006
- Non-enrolment of ovarian cancer patients in clinical trials: reasons and backgroundAnnals of Oncology, 2005
- Optimising Treatment of Elderly Patients with Ovarian CancerDrugs & Aging, 2005
- Enrollment of Elderly Patients in Clinical Trials for Cancer Drug Registration: A 7-Year Experience by the US Food and Drug AdministrationJournal of Clinical Oncology, 2004
- Should advanced age alone be considered a contraindication to systemic lymphadenectomy in gynecologic oncologic patients? A university hospital experience in TurkeyInternational Journal of Gynecologic Cancer, 2004